Adulterated Misbranded Drug Case Study

475 Words1 Page

The Case of the Adulterated, Misbranded or False Claimed Drug
Perusing warning letters in FDA’s Electronic Reading Room yields a plethora of violations regarding adulterated, misbranded or falsely claimed benefits of drugs and supplements. These three issues, consequently, constitute stumbling blocks in drug development or approval and additionally, perhaps also indicate a wanton disregard of compliance in manufacturing and marketing. Do the responsible companies prioritize compliant procedures and documentation? Through investigating three of the most commonly cited reasons for FDA 483 letters, applying them to the above violations, and exploring a culture of compliance, some rationale for causes in this case may be determined.
Insufficient procedures and the adulterated drug
According to compliance-insight.com, the primary cause for an FDA 483 letter is “procedures not in writing, fully followed, 21 CFR 211.22(d)” (Top 10 Reasons for FDA 483). The necessity for well documented and detailed procedures …show more content…

The temptation to engage in exaggeration always exists, but taking unacceptable risks affecting people’s health will get a company in big trouble, as “SOPs not followed / documented, 21 CFR 211.100(b)” rounds out the top ten for precipitating FDA 483 letters (Top).
Company culture of compliance
The above compliance failures illustrate the importance of maintaining a compliant company culture. Managers must create and participate in a top down culture of compliance to succeed. Attempting to change an established noncompliant culture encourages employee resistance and unfortunately often meets with failure. Companies must get this right from the start, or suffer many negative and serious consequences, including the complete withdrawal of substances from FDA

Open Document